High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The SMARCA4 (BRG1) gene, encoding a subunit of SWI/SNF chromatin remodeling complexes, is frequently altered in cancer, suggesting a tumor suppressor function.
• However, recent studies indicate SMARCA4 is essential for tumor cell growth, creating a paradox regarding its role in cancer.

Purpose of the Study:

• To computationally analyze gene expression, prognosis, and clinicopathological data to elucidate the contrasting roles of SMARCA4 and SMARCA2 (BRM) in cancer.
• To investigate the prognostic significance of SMARCA4 and SMARCA2 expression in specific cancer types.

Main Methods:

• Performed a computational meta-analysis of gene expression, prognosis, and clinicopathological data.
• Utilized The Cancer Genome Atlas (TCGA) datasets for liver hepatocellular carcinoma (LIHC) and kidney renal clear cell carcinoma (KIRC) cohorts.
• Compared tumor characteristics based on high versus low expression of SMARCA4 and SMARCA2.

Main Results:

• SMARCA4 is generally overexpressed in tumors, with high expression linked to poor prognosis in LIHC and kidney renal clear cell carcinoma (KIRC).
• Conversely, SMARCA2 is typically downregulated in tumors, and its high expression is associated with a favorable prognosis.
• High SMARCA4 expression correlated with aggressive tumors, whereas high SMARCA2 expression was associated with benign, differentiated tumors in LIHC and KIRC.

Conclusions:

• SMARCA4 and SMARCA2 exhibit opposing roles in cancer development and progression.
• The expression levels of SMARCA4 and SMARCA2 possess significant prognostic value.
• These findings challenge the established view of SMARCA4 as a universal tumor suppressor.